- Home
- BLIN vs CURX Comparison
BLIN vs CURX Comparison
Compare BLIN & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLIN | CURX |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 7.5M |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | BLIN | CURX |
|---|---|---|
| Price | $0.71 | $4.71 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 59.8K | 17.7K |
| Earning Date | 08-13-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,568,000.00 | N/A |
| Revenue This Year | $20.26 | N/A |
| Revenue Next Year | $21.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.66 | $0.21 |
| 52 Week High | $1.42 | $16.39 |
Technical Indicators
Market Signals| Indicator | BLIN | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 35.28 | 51.36 |
| Support Level | $0.69 | $3.79 |
| Resistance Level | $1.05 | $5.29 |
| Average True Range (ATR) | 0.07 | 0.46 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 18.30 | 42.97 |
Price Performance
Historical ComparisonAbout BLIN Bridgeline Digital Inc.
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.